![Transparency Market Researchが調査・発行した産業分析レポートです。ヒトパピローマウイルス・サイトメガロウイルス治療の世界市場2019-2027：薬物クラス別（ヒトパピローマウイルス治療薬[免疫調節剤、角質溶解薬、抗腫瘍薬、シネカテキン]、CMV治療薬[ガンシクロビル/バルガンシクロビル]、フォスカビル{フォスカネット}、シドフォビル{ヴィスティド}、レテルモビル{プレビミス}、その他）、用途別、流通チャンネル別 / Human Papillomavirus and Cytomegalovirus Therapeutics Market (Drug Class: Human Papillomavirus Therapeutics [Immunomodulators, Keratolytics, Antineoplastics, and Sinecatechins] and CMV Therapeutics [Ganciclovir/Valganciclovir, Foscavir {Foscarnet}, Cidofovir {Vistide}, Letermovir {Prevymis}, and Others]; Application: Human Papillomavirus Therapeutics [Genital Warts, Genital Cancer, Oral Papillomas, and Others] and CMV Therapeutics [Retinitis, Gastrointestinal Ulcers, Pneumonia, Encephalitis, and Others]; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TMR2008057資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-84.gif) | • レポートコード：TMR2008057 • 出版社/出版日：Transparency Market Research / 2020年5月 • レポート形態：英文、PDF、277ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートではヒトパピローマウイルス・サイトメガロウイルス治療の世界市場について調査・分析し、序文、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬物クラス別（ヒトパピローマウイルス治療（免疫調節剤、角質溶解薬、抗腫瘍薬、シネカテキン）、サイトメガロウイルス治療（ガンシクロビル/バルガンシクロビル、フォスカビル（フォスカネット）、シドフォビル（ビステイド）、レテルモビル（プレビミス）、その他））分析、用途別（ヒトパピローマウイルス治療（性器いぼ、性器がん、口腔乳頭腫、その他）、サイトメガロウイルス治療（網膜炎、胃腸潰瘍、肺炎、脳炎、その他））分析、流通チャンネル別（病院薬局、小売り薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争マトリックスなどを含め、以下の構成でご提供いたします。 ・序文 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・ヒトパピローマウイルス・サイトメガロウイルス治療の世界市場：薬物クラス別（ヒトパピローマウイルス治療（免疫調節剤、角質溶解薬、抗腫瘍薬、シネカテキン）、サイトメガロウイルス治療（ガンシクロビル/バルガンシクロビル、フォスカビル（フォスカネット）、シドフォビル（ビステイド）、レテルモビル（プレビミス）、その他）） ・ヒトパピローマウイルス・サイトメガロウイルス治療の世界市場：用途別（ヒトパピローマウイルス治療（性器いぼ、性器がん、口腔乳頭腫、その他）、サイトメガロウイルス治療（網膜炎、胃腸潰瘍、肺炎、脳炎、その他）） ・ヒトパピローマウイルス・サイトメガロウイルス治療の世界市場：流通チャンネル別（病院薬局、小売り薬局、オンライン薬局） ・ヒトパピローマウイルス・サイトメガロウイルス治療の世界市場：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争マトリックス |
Human Papillomavirus and Cytomegalovirus Therapeutics Market – Scope of the Report
TMR’s report on the global human papillomavirus and cytomegalovirus therapeutics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides the overall revenue of the global human papillomavirus and cytomegalovirus therapeutics market for the period from 2017 to 2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global human papillomavirus and cytomegalovirus therapeutics market for the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global human papillomavirus and cytomegalovirus therapeutics market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approach to study various phenomena in the global human papillomavirus and cytomegalovirus therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global human papillomavirus and cytomegalovirus therapeutics market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global human papillomavirus and cytomegalovirus therapeutics market.
The report delves into the competitive landscape of the global human papillomavirus and cytomegalovirus therapeutics market. Key players operating in the global human papillomavirus and cytomegalovirus therapeutics market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global human papillomavirus and cytomegalovirus therapeutics market that have been profiled in this report.
Key Questions Answered in Human Papillomavirus and Cytomegalovirus Therapeutics Market Report
What is the sales/revenue generated by each drug class, application, and distribution channel segment of the global human papillomavirus and cytomegalovirus therapeutics market across all regions during the forecast period?
What are the opportunities in the global human papillomavirus and cytomegalovirus therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which region is likely to expand at the fastest CAGR during the forecast period?
Which human papillomavirus and cytomegalovirus therapeutics drug class, application, and distribution channel segments are expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
What is the market share or position of different companies operating in the global market in 2018?
Human Papillomavirus and Cytomegalovirus Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global human papillomavirus and cytomegalovirus therapeutics market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, key industrial developments in terms of merger, acquisition, strategic partnerships, pipeline analysis, and value chain analysis have been provided.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global human papillomavirus and cytomegalovirus therapeutics market in terms of drug class, application, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global human papillomavirus and cytomegalovirus therapeutics market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Human Papillomavirus and Cytomegalovirus Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Value Chain Analysis
5.2. Pipeline Analysis
5.3. Key Mergers, Acquisitions, and Strategic Partnerships
6. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Human Papillomavirus Therapeutics
6.3.1.1. Immunomodulators
6.3.1.2. Keratolytics
6.3.1.3. Antineoplastics
6.3.1.4. Sinecatechins
6.3.2. Cytomegalovirus Therapeutics
6.3.2.1. Ganciclovir/Valganciclovir
6.3.2.2. Foscavir(Foscarnet)
6.3.2.3. Cidofovir(Vistide)
6.3.2.4. Letermovir(Prevymis)
6.3.2.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2027
7.3.1. Human Papillomavirus Therapeutics
7.3.1.1. Genital Warts
7.3.1.2. Genital Cancer
7.3.1.3. Oral Papillomas
7.3.1.4. Others
7.3.2. Cytomegalovirus Therapeutics
7.3.2.1. Retinitis
7.3.2.2. Gastrointestinal Ulcer
7.3.2.3. Pneumonia
7.3.2.4. Encephalitis
7.3.2.5. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Human Papillomavirus Therapeutics
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Online Pharmacies
8.3.2. Cytomegalovirus Therapeutics
8.3.2.1. Hospital Pharmacies
8.3.2.2. Retail Pharmacies
8.3.2.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel
9. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. Human Papillomavirus Therapeutics
10.2.1.1. Immunomodulators
10.2.1.2. Keratolytics
10.2.1.3. Antineoplastics
10.2.1.4. Sinecatechins
10.2.2. Cytomegalovirus Therapeutics
10.2.2.1. Ganciclovir/Valganciclovir
10.2.2.2. Foscavir(Foscarnet)
10.2.2.3. Cidofovir(Vistide)
10.2.2.4. Letermovir(Prevymis)
10.2.2.5. Others
10.3. Market Value Forecast, by Application, 2017–2027
10.3.1. Human Papillomavirus Therapeutics
10.3.1.1. Genital Warts
10.3.1.2. Genital Cancer
10.3.1.3. Oral Papillomas
10.3.1.4. Others
10.3.2. Cytomegalovirus Therapeutics
10.3.2.1. Retinitis
10.3.2.2. Gastrointestinal Ulcer
10.3.2.3. Pneumonia
10.3.2.4. Encephalitis
10.3.2.5. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Human Papillomavirus Therapeutics
10.4.1.1. Hospital Pharmacies
10.4.1.2. Retail Pharmacies
10.4.1.3. Online Pharmacies
10.4.2. Cytomegalovirus Therapeutics
10.4.2.1. Hospital Pharmacies
10.4.2.2. Retail Pharmacies
10.4.2.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. Human Papillomavirus Therapeutics
11.2.1.1. Immunomodulators
11.2.1.2. Keratolytics
11.2.1.3. Antineoplastics
11.2.1.4. Sinecatechins
11.2.2. Cytomegalovirus Therapeutics
11.2.2.1. Ganciclovir/Valganciclovir
11.2.2.2. Foscavir (Foscarnet)
11.2.2.3. Cidofovir (Vistide)
11.2.2.4. Letermovir (Prevymis)
11.2.2.5. Others
11.3. Market Value Forecast, by Application, 2017–2027
11.3.1. Human Papillomavirus Therapeutics
11.3.1.1. Genital Warts
11.3.1.2. Genital Cancer
11.3.1.3. Oral Papillomas
11.3.1.4. Others
11.3.2. Cytomegalovirus Therapeutics
11.3.2.1. Retinitis
11.3.2.2. Gastrointestinal Ulcer
11.3.2.3. Pneumonia
11.3.2.4. Encephalitis
11.3.2.5. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Human Papillomavirus Therapeutics
11.4.1.1. Hospital Pharmacies
11.4.1.2. Retail Pharmacies
11.4.1.3. Online Pharmacies
11.4.2. Cytomegalovirus Therapeutics
11.4.2.1. Hospital Pharmacies
11.4.2.2. Retail Pharmacies
11.4.2.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. Human Papillomavirus Therapeutics
12.2.1.1. Immunomodulators
12.2.1.2. Keratolytics
12.2.1.3. Antineoplastics
12.2.1.4. Sinecatechins
12.2.2. Cytomegalovirus Therapeutics
12.2.2.1. Ganciclovir/Valganciclovir
12.2.2.2. Foscavir (Foscarnet)
12.2.2.3. Cidofovir (Vistide)
12.2.2.4. Letermovir (Prevymis)
12.2.2.5. Others
12.3. Market Value Forecast, by Application, 2017–2027
12.3.1. Human Papillomavirus Therapeutics
12.3.1.1. Genital Warts
12.3.1.2. Genital Cancer
12.3.1.3. Oral Papillomas
12.3.1.4. Others
12.3.2. Cytomegalovirus Therapeutics
12.3.2.1. Retinitis
12.3.2.2. Gastrointestinal Ulcer
12.3.2.3. Pneumonia
12.3.2.4. Encephalitis
12.3.2.5. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Human Papillomavirus Therapeutics
12.4.1.1. Hospital Pharmacies
12.4.1.2. Retail Pharmacies
12.4.1.3. Online Pharmacies
12.4.2. Cytomegalovirus Therapeutics
12.4.2.1. Hospital Pharmacies
12.4.2.2. Retail Pharmacies
12.4.2.3. Online Pharmacies
12.5. Market Value Forecast, by Country, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Human Papillomavirus Therapeutics
13.2.1.1. Immunomodulators
13.2.1.2. Keratolytics
13.2.1.3. Antineoplastics
13.2.1.4. Sinecatechins
13.2.2. Cytomegalovirus Therapeutics
13.2.2.1. Ganciclovir/Valganciclovir
13.2.2.2. Foscavir (Foscarnet)
13.2.2.3. Cidofovir (Vistide)
13.2.2.4. Letermovir (Prevymis)
13.2.2.5. Others
13.3. Market Value Forecast, by Application, 2017–2027
13.3.1. Human Papillomavirus Therapeutics
13.3.1.1. Genital Warts
13.3.1.2. Genital Cancer
13.3.1.3. Oral Papillomas
13.3.1.4. Others
13.3.2. Cytomegalovirus Therapeutics
13.3.2.1. Retinitis
13.3.2.2. Gastrointestinal Ulcer
13.3.2.3. Pneumonia
13.3.2.4. Encephalitis
13.3.2.5. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Human Papillomavirus Therapeutics
13.4.1.1. Hospital Pharmacies
13.4.1.2. Retail Pharmacies
13.4.1.3. Online Pharmacies
13.4.2. Cytomegalovirus Therapeutics
13.4.2.1. Hospital Pharmacies
13.4.2.2. Retail Pharmacies
13.4.2.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2027
14.2.1. Human Papillomavirus Therapeutics
14.2.1.1. Immunomodulators
14.2.1.2. Keratolytics
14.2.1.3. Antineoplastics
14.2.1.4. Sinecatechins
14.2.2. Cytomegalovirus Therapeutics
14.2.2.1. Ganciclovir/Valganciclovir
14.2.2.2. Foscavir (Foscarnet)
14.2.2.3. Cidofovir (Vistide)
14.2.2.4. Letermovir (Prevymis)
14.2.2.5. Others
14.3. Market Value Forecast, by Application, 2017–2027
14.3.1. Human Papillomavirus Therapeutics
14.3.1.1. Genital Warts
14.3.1.2. Genital Cancer
14.3.1.3. Oral Papillomas
14.3.1.4. Others
14.3.2. Cytomegalovirus Therapeutics
14.3.2.1. Retinitis
14.3.2.2. Gastrointestinal Ulcer
14.3.2.3. Pneumonia
14.3.2.4. Encephalitis
14.3.2.5. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Human Papillomavirus Therapeutics
14.4.1.1. Hospital Pharmacies
14.4.1.2. Retail Pharmacies
14.4.1.3. Online Pharmacies
14.4.2. Cytomegalovirus Therapeutics
14.4.2.1. Hospital Pharmacies
14.4.2.2. Retail Pharmacies
14.4.2.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region15. Competition Landscape
15. Market Player – Competition Matrix (By Tier and Size of companies)
15.1. Market Share/Position Analysis, by Company, 2018
15.2. Company Profiles
15.2.1. Merck & Co., Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Bausch & Lomb Incorporated (Bausch Health Companies, Inc.)
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. AbbVie, Inc.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. F. Hoffmann-La Roche Ltd.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5. Company Financials
15.2.5.1. Growth Strategies
15.2.5.2. SWOT Analysis
15.2.6. Mylan N.V.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. Takeda Pharmaceutical Company Limited
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. Teva Pharmaceutical Industries Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Clinigen Group plc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
15.2.10. Pfizer, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Company Financials
15.2.10.3. Growth Strategies
15.2.10.4. SWOT Analysis
15.2.11. Cipla, Inc.
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Company Financials
15.2.11.3. Growth Strategies
15.2.11.4. SWOT Analysis
List of TablesTable 01: Pipeline Analysis, by Human Papillomavirus Therapeutics
Table 02: Pipeline Analysis, by Cytomegalovirus Therapeutics
Table 03: Key Mergers, Acquisitions, and Strategic Partnerships
Table 04: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 05: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 06: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 07: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 08: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 09: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 11: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 12: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 13: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 14: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 15: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 17: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 18: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 19: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 20: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 21: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 22: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 23: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 25: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 26: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 27: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 28: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 30: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 31: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 32: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 33: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 34: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 35: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 36: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 37: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 38: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 39: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 40: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 41: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 42: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 43: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 44: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 45: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 46: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 47: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 48: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 49: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 50: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 51: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027